Bencivenga, L.; Palaia, M.E.; Sepe, I.; Gambino, G.; Komici, K.; Cannavo, A.; Femminella, G.D.; Rengo, G.
Why Do We Not Assess Sympathetic Nervous System Activity in Heart Failure Management: Might GRK2 Serve as a New Biomarker? Cells 2021, 10, 457.
https://doi.org/10.3390/cells10020457
AMA Style
Bencivenga L, Palaia ME, Sepe I, Gambino G, Komici K, Cannavo A, Femminella GD, Rengo G.
Why Do We Not Assess Sympathetic Nervous System Activity in Heart Failure Management: Might GRK2 Serve as a New Biomarker? Cells. 2021; 10(2):457.
https://doi.org/10.3390/cells10020457
Chicago/Turabian Style
Bencivenga, Leonardo, Maria Emiliana Palaia, Immacolata Sepe, Giuseppina Gambino, Klara Komici, Alessandro Cannavo, Grazia Daniela Femminella, and Giuseppe Rengo.
2021. "Why Do We Not Assess Sympathetic Nervous System Activity in Heart Failure Management: Might GRK2 Serve as a New Biomarker?" Cells 10, no. 2: 457.
https://doi.org/10.3390/cells10020457
APA Style
Bencivenga, L., Palaia, M. E., Sepe, I., Gambino, G., Komici, K., Cannavo, A., Femminella, G. D., & Rengo, G.
(2021). Why Do We Not Assess Sympathetic Nervous System Activity in Heart Failure Management: Might GRK2 Serve as a New Biomarker? Cells, 10(2), 457.
https://doi.org/10.3390/cells10020457